RT Journal Article
T1 Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis.
A1 Prieto-Peña, Diana
A1 Remuzgo-Martinez, Sara
A1 Genre, Fernanda
A1 Pulito-Cueto, Veronica
A1 Atienza-Mateo, Belen
A1 Llorca, Javier
A1 Sevilla-Perez, Belen
A1 Ortego-Centeno, Norberto
A1 Marquez, Ana
A1 Lera-Gomez, Leticia
A1 Leonardo, Maria Teresa
A1 Peñalba, Ana
A1 Narvaez, Javier
A1 Martin-Penagos, Luis
A1 Rodrigo, Emilio
A1 Miranda-Filloy, Jose A
A1 Caminal-Montero, Luis
A1 Collado, Paz
A1 Sanchez Perez, Javier
A1 de Argila, Diego
A1 Rubio, Esteban
A1 Leon Luque, Manuel
A1 Blanco-Madrigal, Juan Maria
A1 Galindez-Agirregoikoa, Eva
A1 Gualillo, Oreste
A1 Martin, Javier
A1 Castañeda, Santos
A1 Blanco, Ricardo
A1 Gonzalez-Gay, Miguel A
A1 Lopez-Mejias, Raquel
K1 Gene Regulatory Networks
K1 Gene Frequency
K1 Adolescent
K1 Case-Control Studies
K1 Child
K1 Female
AB Cytokines signalling pathway genes are crucial factors of the genetic network underlying the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular condition. An influence of the interleukin (IL)33- IL1 receptor like (IL1RL)1 signalling pathway on the increased risk of several immune-mediated diseases has been described. Accordingly, we assessed whether the IL33-IL1RL1 pathway represents a novel genetic risk factor for IgAV. Three tag polymorphisms within IL33 (rs3939286, rs7025417 and rs7044343) and three within IL1RL1 (rs2310173, rs13015714 and rs2058660), that also were previously associated with several inflammatory diseases, were genotyped in 380 Caucasian IgAV patients and 845 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when IL33 and IL1RL1 variants were analysed independently. Likewise, no statistically significant differences were found in IL33 or IL1RL1 genotype and allele frequencies when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when IL33 and IL1RL1 haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that the IL33-IL1RL1 signalling pathway does not contribute to the genetic network underlying IgAV.
YR 2021
FD 2021-07-30
LK http://hdl.handle.net/10668/18352
UL http://hdl.handle.net/10668/18352
LA en
NO Prieto-Peña D, Remuzgo-Martínez S, Genre F, Pulito-Cueto V, Atienza-Mateo B, Llorca J, et al.  Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. Sci Rep. 2021 Aug 9;11(1):16163.
NO We are indebted to the patients and healthy controls for their essential collaboration to this study. We also thank the National DNA Bank Repository (Salamanca) for supplying part of the control samples. This study was supported by European Union FEDER funds and `Fondo de Investigaciones Sanitarias´ (Grant PI18/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). DP-P is a recipient of a Río Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) (Grant Number CM20/00006). SR-M is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). BA-M is a recipient of a `López Albo´ Post-Residency Programme funded by Servicio Cántabro de Salud. LL-G is supported by funds from IDIVAL (INNVAL20/06). OG is staff personnel of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (Grant Numbers RD16/0012/0014 (RIER) and PI17/00409). He is beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Programme, project 734899—Olive-Net. RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by ESF (`Investing in your future´) (Grant Number CP16/00033).
DS RISalud
RD Apr 17, 2025